Intermediatebiotechnology
Down Syndrome Genetics
Overview
Down syndrome (1/700 births) is usually trisomy 21 from meiotic nondisjunction: an extra chromosome's ~200 genes overexpressed ~1.5x, disrupting development (intellectual disability, characteristic facies, hypotonia, heart defects, Alzheimer's predisposition via APP). Risk rises with maternal age. Robertsonian 14;21 translocation causes familial cases. Screening (NIPT) and diagnostic testing guide families; research targets DYRK1A and APP pathways.
Learning objectives
- Explain nondisjunction origin
- Describe gene-dosage effects
- Explain maternal-age risk
- Distinguish trisomy, translocation, mosaic forms
The extra chromosome
95% of cases: free trisomy 21 from nondisjunction (usually maternal meiosis I). ~3-4%: Robertsonian translocation (14;21 or 21;21); ~1-2%: mosaic. Chromosome 21 is small (~200-300 genes) but dosage-sensitive: 1.5x expression of DYRK1A, APP, SOD1 and others perturbs neurodevelopment.
No gene is broken; too much normal product disrupts development: the dosage hypothesis.
Phenotype
Intellectual disability (variable, usually mild-moderate), characteristic facial features, hypotonia, single palmar crease; congenital heart defects (~50%), GI atresias, leukemia risk elevated, and near-universal Alzheimer's pathology by 40 (APP triplication -> amyloid). Life expectancy now ~60.
Three APP copies guarantee amyloid pathology: Down syndrome illuminates Alzheimer's mechanisms.
Maternal age and recurrence
Risk: ~1/1500 at 20, ~1/100 at 40, ~1/30 at 45 (aging oocytes missegregate). Free trisomy recurrence ~1% (+ age risk). Translocation carriers: 14;21 carrier mother ~10-15%, father ~1-3%; 21;21 carriers have 100% recurrence: karyotype parents after any translocation case.
Finding a translocation changes everything: parental testing determines recurrence (up to 100%).
Screening and support
First-trimester combined screen, NIPT (cell-free DNA, >99% sensitive for T21), diagnostic amnio/CVS. Management: cardiac repair, thyroid/leukemia surveillance, early intervention, inclusive education. Research: DYRK1A inhibitors, anti-amyloid strategies for DS Alzheimer's.
Testing provides information; decisions belong to families with non-directive counseling.
Key points
- Usually free trisomy 21 from maternal nondisjunction
- 1.5x dosage of ~200 genes disrupts development
- Risk rises steeply with maternal age
- Translocation/mosaic forms differ in recurrence; NIPT screens, amnio diagnoses
Common misconceptions
✓ Truth: Usually sporadic nondisjunction; only translocation forms (3-4%) are inherited.
✓ Truth: Abilities vary widely; many live semi-independently, work, and participate fully in communities.
Practice questions
Q1. Most Down syndrome is caused by
- A point mutation
- Meiotic nondisjunction giving trisomy 21
- A virus
- Imprinting
~95% free trisomy, usually maternal meiosis I error.
Q2. A 21;21 Robertsonian carrier has recurrence risk of
- 1%
- 10%
- ~100%
- 0%
Every gamete gets the translocation chromosome: all children have Down syndrome.
Q3. The Alzheimer's link in Down syndrome involves
- APP triplication
- Tau deletion
- ApoE loss
- Nothing
Three APP copies drive amyloid overproduction.
Click a question to reveal the answer and explanation.
Frequently asked questions
Why does maternal age matter?
Oocytes arrested in meiosis I for decades accumulate segregation errors: cohesin loss with age.
What is mosaic Down syndrome?
Mitotic nondisjunction after fertilization: mixed trisomic/normal cells, often milder phenotype.
Why study APP in Down syndrome?
Triplicated APP drives early Alzheimer's: DS is a genetic model of amyloid pathogenesis.